I make a donation

ADRIFT

Searching the rivaroxaban dosis which enables an adequate anticoagulation evaluated by the level of thrombin generated in patients suffering atrial fibrillation and having a successful percutaneous left atrial appendage closure.

Terminée

Bourses ACTION & PHRA 2022

Colloquium "La cardiologie préventive : nouveautés" (mardi 1er avril 2025)
Réservez vos places !

La Fondation de l'AP-HP attribue le Grand Prix Scientifique 2024 au Pr Gilles Montalescot

La Grande Journée du Coeur (jeudi 26 juin 2025)
Réservez votre après-midi !

P&R Agenda
Au programme prochainement...

objectif

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure

date de réalisation

2017

nombre de patients

nombre de centres participants

National multicentric trial

type de financement

Privé (Fonds de Dotation Action & Bayer)

Référence

NCT03273322

A study conducted by Fonds de Dotation ACTION
Find out details and results on the dedicated page

ADRIFT conducted by Fonds de Dotation ACTION

Autres études

ARCACHON

En cours

To demonstrate the non-inferiority of a strategy of simple clinical follow-up (without non-invasive stress testing) in asymptomatic CAD patients with a prior history of coronary revascularization comp...

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI

AMUNDSEN

En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....